Clustering data with hclust algorithm for (Study ST001275)
Reversed phase UNSPECIFIED ION MODE (Analysis AN002116)| Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 | F14 | F15 | F16 | F17 | F18 | F19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,9S,11R,15S-tetrahydroxy-13E-prostaene | ME299963 | 0.63 | 1.47 | 0.89 | 0.78 | 1.54 | 1.83 | 1.67 | 0.47 | 0.68 | 0.66 | 2.13 | 1.63 | 1.08 | 0.63 | 0.76 | 0.43 | 0.95 | 0.48 | 0.45 |
| 1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol | ME299961 | 0.84 | 0.76 | 1.12 | 0.81 | 1.14 | 1.01 | 0.74 | 1.27 | 0.81 | 1.29 | 1.11 | 1.04 | 1.09 | 0.97 | 1.24 | 0.77 | 0.72 | 0.80 | 1.53 |
| 3-O-(6^-O-octadecanoyl-beta-D-glucopyranosyl)-campest-5-en-3beta-ol | ME299964 | 0.73 | 0.54 | 1.26 | 0.77 | 1.40 | 0.80 | 0.80 | 1.59 | 1.02 | 2.10 | 0.62 | 0.84 | 1.27 | 0.66 | 1.14 | 0.49 | 0.56 | 1.00 | 1.43 |
Factors:
| F1 | Drug treatment:DMSO |
| F2 | Drug treatment:MMV099637 |
| F3 | Drug treatment:MMV652003 |
| F4 | Drug treatment:MMV676600 |
| F5 | Drug treatment:MMV676604 |
| F6 | Drug treatment:MMV687706 |
| F7 | Drug treatment:MMV688179 |
| F8 | Drug treatment:MMV688271 |
| F9 | Drug treatment:MMV688279 |
| F10 | Drug treatment:MMV688467 |
| F11 | Drug treatment:MMV688776 |
| F12 | Drug treatment:MMV688796 |
| F13 | Drug treatment:MMV688797 |
| F14 | Drug treatment:MMV688798 |
| F15 | Drug treatment:MMV688958 |
| F16 | Drug treatment:MMV689028 |
| F17 | Drug treatment:MMV689029 |
| F18 | Drug treatment:MMV690027 |
| F19 | Drug treatment:MMV690028 |
